CGT East Asia (CGTEA) 2025: Advancing the Next Frontier of Regenerative Medicine
Returning after its successful run in 2023, CGT East Asia (CGTEA) 2025 will once again bring together the brightest minds and industry leaders from South Korea, Japan, China, and Taiwan to explore the latest breakthroughs in regenerative medicine. As the region accelerates innovation in gene editing, cell therapy, and personalised medicine, CGTEA 2025 will serve as a critical hub for fostering collaboration between biopharma companies, academic & research institutions, and CDMOs.
This year’s conference will focus on cutting-edge advancements in gene-modified cell therapies, scalable manufacturing for next-generation therapeutics, regulatory frameworks shaping the East Asian market, and strategies to drive commercial success in cell and gene therapy. With an emphasis on bridging research with clinical and commercial applications, the event will provide unparalleled insights into the future of precision medicine.
CGTEA 2025 will be co-located with the 14th Biologics Manufacturing Korea 2025 and ADC Asia Congress 2025, creating a dynamic cross-disciplinary platform for networking, knowledge-sharing, and business growth. Whether you're looking to gain regulatory insights, explore investment opportunities, or forge strategic partnerships, this is the premier event to connect with East Asia’s key players in the cell and gene therapy landscape.
If Korea is the country you are looking at for plentiful opportunities in the cell and gene therapy space, then CGTEA 2025 is where you have to be!
